Abstract
This chapter explores the academic literature and empirical evidence associated with the strategic and tactical opportunities available to pharmaceutical firms confronted with the loss of patent protection on their branded drug. The marketing dimensions of product innovation, pricing, and brand equity options are considered together with exclusivity options available through government regulators such as the US Food and Drug Administration (FDA). These options are then considered in the context of the legal monopolies available to innovators through the policy lenses of intellectual property. This chapter further explores the maxim that sustainable competitive advantage for pharmaceutical innovators is realized at the nexus of marketing choices, intellectual property, and regulatory regimes. Separate examples in gastrointestinal and neurological medications will be used to explore how the various options might be integrated together and used in a time sequenced, longitudinal manner to extend the market advantages and earning levels of the original pharmaceutical compound innovation. Areas of potentially fruitful future academic research are described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Camacho N, De Jong MG, Stremersch S (2012) The effect of customer empowerment on adherence to expert advice. Working Paper, Erasmus University Rotterdam, The Netherlands.
Ding M, Eliashberg J (2002) Structuring the New Product Development Pipeline. Manage Sci 48(3):343–363.
Ding M, Eliashberg J (2008) A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision Making. Manage Sci 54(4):820–834.
Jack A (2011) Medicine approvals slump to lowest in decade. Financial Times. http://www.ft.com/cms/s/0/44fa110a–a014–11e0–a115–00144feabdc0.html#axzz2WdmFAyxS]. Assessed 26 June 2011
Pharmaceutical Research and Manufacturers of America (2010) PhRMA annual membership survey. PhRMA, Washington, DC
Stremersch S, Lemmens A (2009) Sales growth of new pharmaceuticals across the globe: the role of regulatory regimes. Market Sci 28 (4):690–708.
Stremersch S, Van Dyck W (2009) Marketing of the life sciences: a new framework and research agenda for a nascent field. J Market 73(4):4–30
United States Food and Drug Administration (FDA) (2008) FDA releases recommendations regarding use of over-the-counter cough and cold products: products should not be used in children under 2 years of age; Evaluation continues in older populations. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116.htm]. Accessed 28 June 2011
Verniers I, Stremersch S, Croux C (2011) The global entry of new pharmaceuticals: a joint investigation of launch window and price. Int J Res Market 28 (4):295–308
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ding, M., Ding, M., Eliashberg, J., Stremersch, S., Stremersch, S. (2014). The Pharmaceutical Industry: Specificity, Challenges, and What You Can Learn from this Book. In: Ding, M., Eliashberg, J., Stremersch, S. (eds) Innovation and Marketing in the Pharmaceutical Industry. International Series in Quantitative Marketing, vol 20. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7801-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7801-0_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7800-3
Online ISBN: 978-1-4614-7801-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)